Carlumab

Drug Profile

Carlumab

Alternative Names: Anti-CCL2 monoclonal antibody Centocor; Anti-chemokine ligand 2 monoclonal antibody Centocor; Anti-MCP-1 monoclonal antibody Centocor; Anti-monocyte chemoattractant protein 1-monoclonal antibody Centocor; Anti-monocyte chemotactic protein 1 monoclonal antibody Centocor; CNTO-888; Fully human antibody therapeutic for immunology/oncology - Janssen Biotech/MorphoSys

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech
  • Class Antifibrotics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Chemokine CCL2 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Idiopathic pulmonary fibrosis; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 20 May 2013 Final efficacy data from a phase II trial in Idiopathic pulmonary fibrosis released by Janssen
  • 09 May 2012 Carlumab is still in phase II development for Idiopathic pulmonary fibrosis
  • 31 Mar 2012 Discontinued - Phase-I for Solid tumours in Spain (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top